Experience with prazosin in a clinical setting.
In a three-phase study that began in 1969, prazosin was shown to be especially suitable for use in treatment of hypertensive patients with gout, renal disease, or borderline diabetes, owing to the sparing of organ systems often harmed by other antihypertensive drugs.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006977:Hypertension, Renal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011139:Polythiazide / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012110:Reserpine / Q000627:therapeutic use; D013997:Time Factors
D000959:Antihypertensive Agents; D010879:Piperazines; D011799:Quinazolines; D011139:Polythiazide; D012110:Reserpine